Compare KELYA & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KELYA | MGNX |
|---|---|---|
| Founded | 1946 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 340.1M | 280.3M |
| IPO Year | 1994 | 2013 |
| Metric | KELYA | MGNX |
|---|---|---|
| Price | $15.88 | $4.00 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $15.00 | $5.00 |
| AVG Volume (30 Days) | 267.7K | ★ 478.2K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.15 | N/A |
| Revenue | ★ $5,355,600,000.00 | $149,500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.60 | $3.19 |
| P/E Ratio | $106.40 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.98 | $1.30 |
| 52 Week High | $17.75 | $5.08 |
| Indicator | KELYA | MGNX |
|---|---|---|
| Relative Strength Index (RSI) | 46.63 | 45.32 |
| Support Level | $14.53 | $3.83 |
| Resistance Level | $16.50 | $4.38 |
| Average True Range (ATR) | 0.49 | 0.20 |
| MACD | -0.21 | 0.00 |
| Stochastic Oscillator | 14.04 | 13.33 |
Kelly Services Inc is a specialty talent solutions company. The company operates through three reportable segments: i) Enterprise Talent Management, which provides temporary staffing, outsourcing, and permanent placement services across industrial, contact center, and clerical roles, ii) Science, Engineering & Technology, which supplies specialized talent across multiple industries, and iii) Education, which delivers staffing, placement, and executive search services to Pre-K-12 school districts and education organizations in the United States. The majority of the company's revenue is derived from the Enterprise Talent Management segment. Geographically, it generates the maximum revenue from the United States, followed by Europe and the Asia-Pacific Region.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.